BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced that its pivotal Phase 3 Bria-ABC study has screened over 315 and enrolled over 230 patients. BriaCell anticipates reporting topline data in 2026.

BriaCell has received increased interest from cancer centers and continued enrollment momentum following the independent inclusion of its Phase 3 clinical trial in Nature Medicine?s article, ?Eleven clinical trials that will shape medicine in 2026?. The Phase 3 Bria-ABC study is evaluating BriaCell?s lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor versus physician?s choice of treatment in advanced breast cancer. The interim analysis will be conducted after 144 patient events, defined as deaths, have occurred.

Overall survival (OS) is the primary endpoint, and positive results could support full approval of Bria-IMT in patients with metastatic breast cancer. The Bria-IMT combination regimen has received FDA Fast Track designation. BriaCell anticipates reporting topline data in 2026.

For additional information on BriaCell?s pivotal Phase 3 study, please visit ClinicalTrials.gov NCT06072612.